Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies

References

• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695–747.
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Symons JA, Deval J. Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond. Antiviral Res. 2018;155:76–88.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al. Drug repurposing: progress, challenges and recommendations: a review article on drug repurposing. Nat Rev Drug Discov. 2019;18(1):41–58.
   PubMed Web of Science ®Google Scholar
• a) Dotolo S, Marabotti A, Facchiano A, Tagliaferri R. A review on drug repurposing applicable to COVID-19. Brief Bioinform. 2021;22(2):726–741. b) Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508. c) Parvathaneni V, Gupta V. Utilizing drug repurposing against COVID-19 – efficacy, limitations, and challenges. Life Sci. 2020;259:118275. d) De Savi C, Hughes DL, Kvaerno L. Quest for a COVID-19 cure by repurposing small-molecule drugs: mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev. 2020;24(6):940–976.
   PubMed Web of Science ®Google Scholar
• a) Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119. b) Arshad U, Pertinez H, Box H, et al. Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775–790.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941–1953.
   PubMed Web of Science ®Google Scholar
• a) Al-Muhsen S, Al-Numair NS, Saheb Sharif-Askari N, Basamh R, Alyounes B, Jabaan A, Saheb Sharif-Askari F, Alosaimi MF, Alsohime F, Halwani R, et al. Favipiravir effectiveness and safety in hospitalized moderate-severe COVID-19 patients: observational prospective multicenter investigation in Saudi Arabia. Front Med (Lausanne). 2022;9:826247. b) McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, Bryant M, Garlick J, Paterson A, Lee SJ, et al. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine. 2022;54:101703.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, RECOVERY Collaborative Group, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586–1593.
   PubMed Web of Science ®Google Scholar
• Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, Höbartner C, Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–746.
   PubMed Web of Science ®Google Scholar
• Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv. 2023;9(13):eade8778.
   PubMed Web of Science ®Google Scholar
• a) Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov. 2002;1(1):65–75. b) Alonzi DS, Scott KA, Dwek RA, Zitzmann N. Iminosugar antivirals: the therapeutic sweet spot. Biochem Soc Trans. 2017;45(2):571–582.
   PubMed Web of Science ®Google Scholar
  c) Norton PA, Gu B, Block TM. Iminosugars as antiviral agents. In: Compain P, Martin OR, editors. Iminosugars: from synthesis to therapeutic applications. Chichester, UK: John Wiley & Sons, Ltd; 2007. p. 209–224.
   Google Scholar
• Tharappel AM, Samrat SK, Li Z, Li H. Targeting crucial host factors of SARS-CoV-2. ACS Infect Dis. 2020;6(11):2844–2865.
   PubMed Web of Science ®Google Scholar
• Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res. 2013;98(3):432–440.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Alonzi DS, Hill JC, Caputo AT, Roversi P, Kiappes JL, Sheets N, Duchars M, Dwek RA, Biggins J, et al. Targeting endoplasmic reticulum α-glucosidase I with a single-dose iminosugar treatment protects against lethal influenza and dengue virus infections. J Med Chem. 2020;63(8):4205–4214.
   PubMed Web of Science ®Google Scholar
• Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, Cuconati A, Lin H, Block TM, Chang J, et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother. 2015;59(1):206–216.
   PubMed Web of Science ®Google Scholar
• Williams SJ, Goddard-Borger ED. ED. α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. Biochem Soc Trans. 2020;48(3):1287–1295.
   PubMed Web of Science ®Google Scholar
• Dwek RA, Bell JI, Feldmann M, Zitzmann N. Host-targeting oral antiviral drugs to prevent pandemics. Lancet. 2022;399(10333):1381–1382.
   PubMed Web of Science ®Google Scholar
• Chang J, Block TM, Guo J-T. Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res. 2013;99(3):251–260.
   PubMed Web of Science ®Google Scholar
• a) Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs. 2014;74(1):61–74. b) Patterson MC, Vecchio D, Prady H. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765–772.
   PubMed Web of Science ®Google Scholar
• Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008;4(2):425–431.
   PubMedGoogle Scholar
• Lahav D, Liu B, van den Berg RJBHN, van den Nieuwendijk AMCH, Wennekes T, Ghisaidoobe AT, Breen I, Ferraz MJ, Kuo C-L, Wu L, et al. A fluorescence polarization activity-based protein profiling assay in the discovery of potent, selective inhibitors for human nonlysosomal glucosylceramidase. J Am Chem Soc. 2017;139(40):14192–14197.
   PubMed Web of Science ®Google Scholar
• Sayce AC, Alonzi DS, Killingbeck SS, Tyrrell BE, Hill ML, Caputo AT, Iwaki R, Kinami K, Ide D, Kiappes JL, et al. Iminosugars inhibit dengue virus production via inhibition of ER alpha-glucosidases—not glycolipid processing enzymes. PLoS Negl Trop Dis. 2016;10(3):e0004524.
   PubMed Web of Science ®Google Scholar
• Flanagan JJ, Rossi B, Tang K, Wu X, Mascioli K, Donaudy F, Tuzzi MR, Fontana F, Cubellis MV, Porto C, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009;30(12):1683–1692.
   PubMed Web of Science ®Google Scholar
• a) Elbein AD. Glycosidase inhibitors: inhibitors of N‐linked oligosaccharide processing. Faseb J. 1991;5(15):3055–3063. b) Tulsiani DR, Harris TM, Touster O. Swainsonine inhibits the biosynthesis of complex glycoproteins by inhibition of golgi mannosidase II. J Biol Chem. 1982;257(14):7936–7939.
   PubMed Web of Science ®Google Scholar
• a) Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW. A phase I study of swainsonine in patients with advanced malignancies. Cancer Res. 1994;54(6;54(6):1450–1457. b) Goss PE, Reid CL, Bailey D, et al. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res. 1997;3(7):1077–1086. c) Shaheen PE, Stadler W, Elson P, Knox J, Winquist E, Bukowski RM. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest New Drugs. 2005;23(6):577–581.
   PubMed Web of Science ®Google Scholar
• Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459–468.
   PubMed Web of Science ®Google Scholar
• a) Pavlović D, Neville DCA, Argaud O, Blumberg B, Dwek RA, Fischer WB, Zitzmann N. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA. 2003;100(10):6104–6108. b) Durantel D, Branza-Nichita N, Carrouée-Durantel S, Butters TD, Dwek RA, Zitzmann N. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol. 2001;75(19):8987–8998.
   PubMed Web of Science ®Google Scholar
• a) McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79(5):543–554. b) McCafferty EH, Scott LJ. Correction to: Migalastat: a review in Fabry disease. Drugs. 2019;79(5):543–554.
   PubMed Web of Science ®Google Scholar
• Mahoney R, Lee GK, Zepeda JP, et al. Severe manifestations and treatment of COVID-19 in a transplanted patient with Fabry disease. Mol Genet Metab Rep. 2021;29:100802.
   PubMed Web of Science ®Google Scholar
• Han N, Hwang W, Tzelepis K, Schmerer P, Yankova E, MacMahon M, Lei W, M Katritsis N, Liu A, Felgenhauer U, et al. Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies. Sci Adv. 2021;7(27):eabh3032.
   PubMed Web of Science ®Google Scholar
• Caputo AT, Alonzi DS, Marti L, Reca I-B, Kiappes JL, Struwe WB, Cross A, Basu S, Lowe ED, Darlot B, et al. Structures of mammalian ER α-glucosidase II capture the binding modes of broad-spectrum iminosugar antivirals. Proc Natl Acad Sci USA. 2016;113(32):E4630–8.
   PubMed Web of Science ®Google Scholar
• a) O'Keefe S, Roebuck QP, Nakagome I, Hirono S, Kato A, Nash R, High S. Characterizing the selectivity of ER α-glucosidase inhibitors. Glycobiology. 2019;29(7):530–542. b) Satoh T, Toshimori T, Yan G, et al. Structural basis for two-step glucose trimming by glucosidase II involved in ER glycoprotein quality control. Sci Rep. 2016;6(1):20575.
   PubMed Web of Science ®Google Scholar
• Satoh T, Toshimori T, Yan G, et al. 5DL0 Crystal structure of glucosidase II alpha subunit (Glc1Man2-bound from). Internet]. RCSB PDB. 2016; Available from: rcsb.org/structure/5DL0.
   Google Scholar
• RCSB Protein Data Bank [Internet]. Available from: rcsb.org. (last accessed 22 December 2022).
   Google Scholar
• Du Y, Ye H, Gill T, Wang L, Guo F, Cuconati A, Guo J-T, Block TM, Chang J, Xu X, et al. N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections. Bioorg Med Chem Lett. 2013;23(7):2172–2176.
   PubMed Web of Science ®Google Scholar
• Prell E, Korb C, Kluge R, Ströhl D, Csuk R. Amplification of the inhibitory activity and reversal of the selectivity of miglitol by C(2′)-monofluorination. Arch Pharm (Weinheim)). 2010;343(10):583–589.
   PubMed Web of Science ®Google Scholar
• De Crescenzo GA, Getman DP. 1,4-Dideoxy-4-fluoronojirimycin. Eur. Pat. Appl. EP481950 A2; 1992.
   Google Scholar
• Hentges A, Bause E. Affinity purification and characterization of glucosidase II from pig liver. Biol Chem. 1997;378(9):1031–1038.
   PubMed Web of Science ®Google Scholar
• Andersen SM, Ebner M, Ekhart CW, Gradnig G, Legler G, Lundt I, Stütz AE, Withers SG, Wrodnigg T. Two isosteric fluorinated derivatives of the powerful glucosidase inhibitors, 1-deoxynojirimycin and 2,5-dideoxy-2,5-imino-d-mannitol: syntheses and glucosidase-inhibitory activities of 1,2,5-trideoxy-2-fluoro-1,5-imino-d-glucitol and of 1,2,5-trideoxy-1-fluoro-2,5-imino-d-mannitol. Carbohydr Res. 1997;301(3-4):155–166.
   Web of Science ®Google Scholar
• Berger A, Dax K, Gradnig G, Grassberger V, Stütz AE, Ungerank M, Legler G, Bause E. Synthesis and biological activity of C-6 modified derivatives of the glucosidase inhibitor 1-deoxynojirimycin. Bioorg Med Chem Lett. 1992;2(1):27–32.
   Web of Science ®Google Scholar
• Tarko L, Hirtopeanu A. QSAR study regarding the inhibitory activity of some iminosugars against α-glucosidase. Rev Chim. 2016;67(1):13–16.
   Web of Science ®Google Scholar
• Ma J, Wu S, Zhang X, Guo F, Yang K, Guo J, Su Q, Lu H, Lam P, Li Y, et al. Ester Prodrugs of IHVR-19029 with enhanced oral exposure and prevention of gastrointestinal glucosidase interaction. ACS Med Chem Lett. 2017;8(2):157–162.
   PubMed Web of Science ®Google Scholar
• Kiappes JL, Hill ML, Alonzi DS, Miller JL, Iwaki R, Sayce AC, Caputo AT, Kato A, Zitzmann N. ToP-DNJ, a selective inhibitor of endoplasmic reticulum α-glucosidase II exhibiting antiflaviviral activity. ACS Chem Biol. 2018;13(1):60–65.
   PubMed Web of Science ®Google Scholar
• Cendret V, Legigan T, Mingot A, Thibaudeau S, Adachi I, Forcella M, Parenti P, Bertrand J, Becq F, Norez C, et al. Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors. Org Biomol Chem. 2015;13(43):10734–10744.
   PubMed Web of Science ®Google Scholar
• Zamoner LOB, Aragão-Leoneti V, Carvalho I. Iminosugars: Effects of stereochemistry, ring size, and N-substituents on glucosidase activities. Pharmaceuticals (Basel). 2019;12(3):108.
   PubMedGoogle Scholar
• a) Mykhailiuk PK. Saturated bioisosteres of benzene: where to go next? Org Biomol Chem. 2019;17(11):2839–2849. b) Measom ND, Down KD, Hirst DJ, Jamieson C, Manas ES, Patel VK, Somers DO. Investigation of a bicyclo[1.1.1]pentane as a phenyl replacement within an LpPLA 2 inhibitor. ACS Med Chem Lett. 2017;8(1):43–48. c) Stepan AF, Subramanyam C, Efremov IV, Dutra JK, O'Sullivan TJ, DiRico KJ, McDonald WS, Won A, Dorff PH, Nolan CE, et al. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor. J Med Chem. 2012;55(7):3414–3424.
   PubMed Web of Science ®Google Scholar
• Rowland RJ, Wu L, Davies GJ. 6IBK Crystal structure of human alpha-galactosidase A in complex with alpha-galactose configured cyclosulfamidate ME763. Rcsb Pdb. 2019.
   Google Scholar
• a) Hill CH, Viuff AH, Spratley SJ, Salamone S, Christensen SH, Read RJ, Moriarty NW, Jensen HH, Deane JE. Azasugar inhibitors as pharmacological chaperones for Krabbe disease. Chem Sci. 2015;6(5):3075–3086. b) Won J-S, Singh AK, Singh I. Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe’s disease. J Neurosci Res. 2016;94(11):990–1006.
   PubMed Web of Science ®Google Scholar
• Ayers BJ, Ngo N, Jenkinson SF, Martínez RF, Shimada Y, Adachi I, Weymouth-Wilson AC, Kato A, Fleet GWJ. Glycosidase inhibition by all 10 stereoisomeric 2,5-dideoxy-2,5-iminohexitols prepared from the enantiomers of glucuronolactone. J Org Chem. 2012;77(18):7777–7792.
   PubMed Web of Science ®Google Scholar
• Kato A, Yamashita Y, Nakagawa S, Koike Y, Adachi I, Hollinshead J, Nash RJ, Ikeda K, Asano N. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010;18(11):3790–3794.
   PubMed Web of Science ®Google Scholar
• Sobala ŁF, Fernandes PZ, Hakki Z, Thompson AJ, Howe JD, Hill M, Zitzmann N, Davies S, Stamataki Z, Butters TD, et al. Structure of human endo-α-1,2-mannosidase (MANEA), an antiviral host-glycosylation target. Proc Natl Acad Sci USA. 2020;117(47):29595–29601.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Li H, Wischnewski H, Prasad A, Kerley-Hamilton JS, Mitchell T, Walling AJ, Davidson RC, Wildt S, Gerngross TU, et al. Intact α-1,2-endomannosidase is a typical type II membrane protein. Glycobiology. 2005;15(6):615–624.
   PubMed Web of Science ®Google Scholar
• Koyama R, Kano Y, Kikushima K, Mizutani A, Soeda Y, Miura K, Hirano T, Nishio T, Hakamata W. A novel Golgi mannosidase inhibitor: molecular design, synthesis, enzyme inhibition, and inhibition of spheroid formation. Bioorg Med Chem. 2020;28(11):115492.
   PubMed Web of Science ®Google Scholar
• a) Clemons M, Danson S, Howell A. Tamoxifen (‘Nolvadex’): a review. Cancer Treat Rev. 2002;28(4):165–180. b) Heel RC, Brogden RN, Speight TM, Avery GS. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs. 1978;16(1):1–24. c) Botti V, Menzel O, Staedler D. A state-of-the-art review of tamoxifen as a potential therapeutic for Duchenne muscular dystrophy. Front Pharmacol. 2022;13:1030785.
   PubMed Web of Science ®Google Scholar
• Koyama R, Hakamata W, Hirano T, Nishio T. Identification of small-molecule inhibitors of human Golgi mannosidase via a drug repositioning screen. Chem Pharm Bull (Tokyo). 2018;66(6):678–681.
   PubMed Web of Science ®Google Scholar
• a) Wang J, Zhao Y, Zhao W, Wang P, Li J. Total synthesis of N -butyl-1-deoxynojirimycin. J Carbohydr Chem. 2016;35(8-9):445–454. b) Schäfer W, Helferich B. α-Methyl d-glucoside. Org Synth. 1941;1:364–366. c) Li CW, Dong HJ, Cui CB. The synthesis and antitumor activity of twelve galloyl glucosides. Molecules. 2015;20(2):2034–2060. d) Fernández-Herrera MA, Mohan S, López-Muñoz H, Hernández-Vázquez JMV, Pérez-Cervantes E, Escobar-Sánchez ML, Sánchez-Sánchez L, Regla I, Pinto BM, Sandoval-Ramírez J, et al. Synthesis of the steroidal glycoside (25R)-3β,16β-diacetoxy-12,22-dioxo-5α-cholestan-26-yl β-d-glucopyranoside and its anti-cancer properties on cervicouterine HeLa, CaSki, and ViBo cells. Eur J Med Chem. 2010;45(11):4827–4837. e) Koppolu SR, Niddana R, Balamurugan R. Gold-catalysed glycosylation reaction using an easily accessible leaving group. Org Biomol Chem. 2015;13(18):5094–5097. f) Ma Y, Liu S, Xi Y, Li H, Yang K, Cheng Z, Wang W, Zhang Y. Highly stereoselective synthesis of aryl/heteroaryl- C-nucleosides via the merger of photoredox and nickel catalysis. Chem Commun (Camb)). 2019;55(97):14657–14660. g) Compain P, Decroocq C, Iehl J, Holler M, Hazelard D, Mena Barragán T, Ortiz Mellet C, Nierengarten J‐F. Glycosidase inhibition with fullerene iminosugar balls: a dramatic multivalent effect. Angew Chem Int Ed. 2010;49(33):5753–5756.
   Web of Science ®Google Scholar
• a) Marjanovic Trajkovic J, Milanovic V, Ferjancic Z, Saicic RN. On the asymmetric induction in proline-catalyzed aldol reactions: reagent-controlled addition reactions of 2,2-dimethyl-1,3-dioxane-5-one to acyclic chiral α-branched aldehydes. Eur J Org Chem. 2017;2017(41):6146–6153. b) Ferjancic Z, Saicic RN. Combining organocatalyzed aldolization and reductive amination: an efficient reaction sequence for the synthesis of iminosugars. Eur J Org Chem. 2021;2021(22):3241–3250.
   Web of Science ®Google Scholar
• Marjanovic J, Ferjancic Z, Saicic RN. Organocatalyzed synthesis of (−)-4-epi-fagomine and the corresponding pipecolic acids. Tetrahedron. 2015;71(38):6784–6789.
   Web of Science ®Google Scholar
• Trajkovic JM, Ferjancic Z, Saicic RN. A short stereoselective synthesis of (+)-aza-galacto-fagomine (AGF). Tetrahedron. 2017;73(18):2629–2632.
   Web of Science ®Google Scholar
• Carabateas PM, Surrey AR, Harris LS. and Antitussive activity of a new heterocyclic ring system. some 1,2-diazabicyclo[2.2.2]octanes. J Med Chem. 1964;7(3):293–297.
   PubMed Web of Science ®Google Scholar
• a) Trajkovic M, Balanac V, Ferjancic Z, Saicic RN. Total synthesis of (+)-swainsonine and (+)-8-epi-swainsonine. RSC Adv. 2014;4(96):53722–53724. b) Trajkovic M, Pavlovic M, Bihelovic F. Total synthesis of (+)-swainsonine, (–)-swainsonine, (+)-8-epi-swainsonine and (+)-dideoxy-imino-lyxitol by an organocatalyzed aldolization/reductive amination sequence. Nat Prod Commun. 2022;17(4):1934578X2210916.
   Web of Science ®Google Scholar
• a) Cao Y, Yang R, Lee I, Zhang W, Sun J, Wang W, Meng X. Characterization of the SARS‐CoV‐2 E protein: sequence, structure, viroporin, and inhibitors. Protein Sci. 2021;30(6):1114–1130. . b) Wang K, Xie S, Sun B. Viral proteins function as ion channels. Biochim Biophys Acta. 2011;1808(2):510–515.
   PubMed Web of Science ®Google Scholar
  c) See Ref. 28 and in particular Ref. 28b, in which the authors contest the correlation of the inhibitory activity of DNJ on ER α-glucosidases with its anti-BVDV activity. [33813796]
   Google Scholar
• a) Chang AY, Chau V, Landas JA, et al. Preparation of calcium competent Escherichia coli and heat-shock transformation. JEMI Methods. 2017;1:22–25. b) Yamamoto K, Nakayama A, Yamamoto Y, Tabata S. Val216 decides the substrate specificity of α-glucosidase in Saccharomyces cerevisiae. Eur J Biochem. 2004;271(16):3414–3420.
   Google Scholar
• Trombetta ES, Simons JF, Helenius A. Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit. J Biol Chem. 1996;271(44):27509–27516.
   PubMed Web of Science ®Google Scholar
• a) Prodanović R, Milosavić N, Jovanović S, Prodanović O, Ćirković Veličković T, Vujčić Z, Jankov RM. Activity and stability of soluble and immobilized α-glucosidase from baker’s yeast in cosolvent systems. Biocatal Biotransform. 2006;24(3):195–200.
   Web of Science ®Google Scholar
  b) https://www.graphpad.com/quickcalcs/linear1/. (last accessed 10 March 2023).
   Google Scholar
  c) Guce AI, Clark NE, Salgado EN, Ivanen DR, Kulminskaya AA, Brumer H, Garman SC. Catalytic mechanism of human α-galactosidase. J Biol Chem. 2010;285(6):3625–3632.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Igarashi Y, Ichikawa M, Suhara Y. 1-N-Iminosugars: potent and selective inhibitors of β-glycosidases. J Am Chem Soc. 1998;120(13):3007–3018.
   Web of Science ®Google Scholar
• Bhuma N, Burade SS, Louat T, Herman J, Kawade S, Doshi PJ, Dhavale DD. Fluorinated piperidine iminosugars and their N-alkylated derivatives: synthesis, conformational analysis, immunosuppressive and glycosidase inhibitory activity studies. Tetrahedron. 2018;74(8):852–858.
   Web of Science ®Google Scholar
• a) Li Y, Liu D, Wang Y, Su W, Liu G, Dong W. The importance of glycans of viral and host proteins in enveloped virus infection. Front Immunol. 2021;12:638573. b) Jan J-T, Cheng T-JR, Juang Y-P, et al. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2021;118(5):e2021579118.
   PubMedGoogle Scholar
• Nunes-Santos CJ, Kuehn HS, Rosenzweig SD. N-glycan modification in COVID-19 pathophysiology: in vitro structural changes with limited functional effects. J Clin Immunol. 2021;41(2):335–344.
   PubMed Web of Science ®Google Scholar
• Guo, et al. reported that miglustat inhibits the entry of SARS-CoV into a host cell via a post-receptor-binding mechanism. See Ref.16.
   Google Scholar
• Rajasekharan S, Milan Bonotto R, Nascimento Alves L, Kazungu Y, Poggianella M, Martinez-Orellana P, Skoko N, Polez S, Marcello A. Inhibitors of protein glycosylation are active against the coronavirus severe acute respiratory syndrome coronavirus SARS-CoV-2. Viruses. 2021;13(5):808.
   PubMed Web of Science ®Google Scholar
• a) Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C, Pöhlmann S, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585(7826):588–590. b) Funnell SGP, Dowling WE, Muñoz-Fontela C, Gsell P-S, Ingber DE, Hamilton GA, Delang L, Rocha-Pereira J, Kaptein S, Dallmeier KH, et al. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nat Commun. 2020;11(1):4253. c) Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585:584–587.
   PubMed Web of Science ®Google Scholar
• Clarke EC, Nofchissey RA, Ye C, Bradfute SB. The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication. Glycobiology. 2021;31(4):378–384.
   PubMed Web of Science ®Google Scholar
• Franco EJ, Warfield KL, Brown AN. UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines. Front Biosci (Landmark Ed)). 2022;27(1):3.
   PubMed Web of Science ®Google Scholar
• Reyes H, Du Y, Zhou T, et al. Glucosidase inhibitors suppress SARS-CoV-2 in tissue culture and may potentiate. bioRxiv. 2021;2021.05.14.444190.
   Google Scholar
• Karade SS, Franco EJ, Rojas AC, et al. Structure-based design of potent iminosugar inhibitors of endoplasmic reticulum α-glucosidase I with anti-SARS-CoV-2 activity. J Med Chem. 2023;66(4):2744–2760.
   PubMedGoogle Scholar
• Overkleeft HS, Renkema GH, Neele J, et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem. 1998;273(41):26522–26527.
   PubMed Web of Science ®Google Scholar
• Zu S, Luo D, Li L, et al. Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry. Signal Transduct Target Ther. 2021;6(1):435.
   PubMed Web of Science ®Google Scholar
• Principle of multivalency:
   Google Scholar
  a) Ramos-Soriano J, Rojo J. Glycodendritic structures as DC-SIGN binders to inhibit viral infections. Chem Commun (Camb). 2021;57(42):5111–5126. b) Schneider JP, Tommasone S, Della Sala P, et al. Synthesis and glycosidase inhibition properties of calix[8]arene-based iminosugar click clusters. Pharmaceuticals. 2020;13(11):366. c) Illescas BM, Rojo J, Delgado R, et al. Multivalent glycosylated nanostructures to inhibit Ebola virus infection. J Am Chem Soc. 2017;139(17):6018–6025.
   PubMed Web of Science ®Google Scholar
• а) Protein Preparation Wizard. Epik. New York (NY): Schrödinger, LLC; 2021. b) Impact. New York (NY): Schrödinger, LLC; c) Prime. New York (NY): Schrödinger, LLC; 2021. d) Madhavi Sastry G, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234.
   Google Scholar
• Schrödinger release 2021–4: Maestro. New York (NY): Schrödinger, LLC.
   Google Scholar
• a) Schrödinger Release 2021-1: Epik, Schrödinger, LLC, New York, NY, 2021. b) Shelley JC, Cholleti A, Frye LL, et al. Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 2007;21(12):681–691.
   Google Scholar
• a) Schrödinger release 2021–4: Glide. New York (NY): Schrödinger, LLC; 2021. b) Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49:6177–6196.
   Google Scholar
• BIOVIA Discovery Studio 2021 Client. San Diego: Dassault Systèmes; 2021.
   Google Scholar
• a) Harwood LM. Dry-column flash chromatography. Aldrichimica Acta. 1985;18(1):25.
   Google Scholar
  b) Furniss BS, Hannaford AJ, Smith PWG, et al. Dry-column flash chromatography. Vogel’s Textbook of Practical Organic Chemistry. 5th ed. London: Longman Scientific & Technical; 1989. p. 220.
   Google Scholar
  c) Pedersen D, Rosenbohm C. Dry column vacuum chromatography. Synthesis (Stuttg). 2004; 2001(16):2431–2434.
   Google Scholar
• Perrin DD, Armarego WLF. Purification of laboratory chemicals. 3rd ed. Oxford: Pergamon Press; 1988.
   Google Scholar
• Messner M, Kozhushkov SI, de Meijere A. Nickel- and palladium-catalyzed cross-coupling reactions at the bridgehead of bicyclo[1.1.1]pentane derivatives - a convenient access to liquid crystalline compounds containing bicyclo[1.1.1]pentane moieties. Eur J Org Chem. 2000;2000(7):1137–1155.
   Web of Science ®Google Scholar
• Caputo DFJ, Arroniz C, Dürr AB, Mousseau JJ, Stepan AF, Mansfield SJ, Anderson EA. Synthesis and applications of highly functionalized 1-halo-3-substituted bicyclo[1.1.1]pentanes. Chem Sci. 2018;9(23):5295–5300.
   PubMed Web of Science ®Google Scholar
• Wennekes T, Lang B, Leeman M, Marel G. A v d, Smits E, Weber M, Wiltenburg J. v, Wolberg M, Aerts JMFG, Overkleeft HS. Large-scale synthesis of the glucosylceramide synthase inhibitor N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin. Org Process Res Dev. 2008;12(3):414–423.
   Web of Science ®Google Scholar
• Wennekes T, Meijer AJ, Groen AK, Boot RG, Groener JE, van Eijk M, Ottenhoff R, Bijl N, Ghauharali K, Song H, et al. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J Med Chem. 2010;53(2):689–698.
   PubMed Web of Science ®Google Scholar